Ms Barbara Paldus | CEO
Finesse Solutions, LLC

	Barb was most recently the CTO of Picarro, a company she founded in 1998. At Picarro, she was responsible for technology, research, and business development, which led to a solid-state Cyan laser product in 2003 and cavity ring-down spectroscopy products in 2004. Barb is currently a partner at Skymoon Ventures. Barb received both her Ph.D. (1998) and M.S.E.E. (1994) degrees in electrical engineering from Stanford University and he B.S.E.E. and BMath from University of Waterloo (1993).	Share this

Appearances at this years' conference:

World Vaccine Manufacturing Congress Asia Day One - 12 June 2012

@ 12.00

Smart Vaccine Manufacturing: Fast-tracking to GMP single-use factory

Appreciating the reality of scaling to 2000L in single-use
Driving industrial automation for large-scale vaccine production
Optimising process scale-up from PD to GMP

› Ms Barbara Paldus, CEO, Finesse Solutions, LLC

Attend ›

the awards

Developing effective production strategies for multi-vaccine manufacturing in Asia

Evaluating specific challenges associated with manufacturing different vaccines
Developing robust approaches to fully utilise production facility
Exploring the different strategies available for ensuring quality control and regulatory compliance

Growing vaccine pipeline value through effective partnering and investment strategies in Asia

Asia contains a wide variety of vaccine markets, each with different advantages due to cultural, economic and geographic differences. Identifying the right partners to develop vaccines from initial R&D through trials to commercialization requires a strategic and well defined approach.
This workshop will assist participants in understanding how to approach the Asian market for external research and development and how to successfully build a pipeline through strategic partnerships.

Transitioning existing biologics processes into single use technology platform to enable global deployment

Factors to consider before implementation: performance equivalency, quality, logistics and business needs
Evaluating which single-use equipment to utilize, considering cost and which stage should be implemented first
Examining before and after implementation for optimum efficiency

Optimising cost-effective Japanese Encephalitis (JE) vaccine development in Asia

Evaluating current development on inactivated and live molecular JE vaccine for the global population
Tapping on lessons learnt from producing the vaccine in Asia
Case study: Assessing the long term immunity of live attenuated Japanese encephalitis chimeric virus vaccine

Innovative vaccine design: Important chemistry, manufacturing and controls (CMC) issues in adjuvant development

Uncovering new concepts and knowledge about innovative vaccine design; innate immunity and beyond
Tapping on advanced technologies of immune-manipulation and delivery system in Japan
Overcoming regulatory hurdles and harnessing the potential for adjuvants in Japan; key factors for very safe and efficacious vaccines

Innovative International Vaccine Developments

Leading global and Asian biotechs, pharmas and research institutes will showcase their latest vaccine developments looking for potential partners globally and across Asia. Potential partnerships run from research and development to licensing and collaboration in vaccine commercialization.

sponsor World Vaccine Congress Asia 2012 ›

Asia'a largest vaccine event

Ms Barbara Paldus | CEO Finesse Solutions, LLC

Share this